Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections

被引：23

作者：

Carrillo-Muñoz, AJ

Quindós, G

Ruesga, M

Alonso, R

del Valle, O

Hernández-Molina, JM

McNicholas, P

Loebenberg, D

Santos, P

机构：

[1] ACIA, Dept Microbiol, E-08080 Barcelona, Spain

[2] Univ Basque Country, Fac Med, Dept Inmunol Microbiol & Parasitol, E-48080 Bilbao, Spain

[3] Hosp Valle De Hebron, Microbiol Serv, Barcelona, Spain

[4] Hosp Inmaculada, Microbiol Serv, Huercal Overa, Almeria, Spain

[5] Schering Plough Res Inst, Kenilworth, NJ USA

[6] Hosp Pediat Pablo Garrahan, Buenos Aires, DF, Argentina

来源：

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2005年 / 55卷 / 03期

关键词：

susceptibility; opportunistic; Candida;

D O I：

10.1093/jac/dki022

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Objectives: The in vitro antifungal activity of posaconazole was compared with that of fluconazole and amphotericin B. Materials and methods: A microdilution method (M27-A2) was used with 331 clinical yeast isolates. Results: The geometric mean MICs of posaconazole, fluconazole and amphotericin B were 0.16, 0.91 and 0.15 mg/L, respectively. Posaconazole was markedly more active than fluconazole and was active against 9/11 fluconazole-resistant Candida albicans, and five Candida glabrata had an MIC of posaconazole of 16 mg/L. Conclusions: These data indicate that posaconazole is a potentially effective antifungal agent for the treatment of mycoses caused by yeasts.

引用

收藏

页码：317 / 319

页数：3

相关论文

共 28 条

[11] SCH56592 treatment of murine invasive aspergillosis [J].

Graybill, JR ;

Bocanegra, R ;

Najvar, LK ;

Luther, MF ;

Loebenberg, D .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (04) :539-542

[12] Efficacy of SCH56592 in a rabbit model of invasive aspergillosis [J].

Kirkpatrick, WR ;

McAtee, RK ;

Fothergill, AW ;

Loebenberg, D ;

Rinaldi, MG ;

Patterson, TF .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (03) :780-782

[13] Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp. [J].

Law, D ;

Moore, CB ;

Denning, DW .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (10) :2310-2311

[14] Treatment of murine fusariosis with SCH 56592 [J].

Lozano-Chiu, M ;

Arikan, S ;

Paetznick, VL ;

Anaissie, EJ ;

Loebenberg, D ;

Rex, JH .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (03) :589-591

[15] Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis [J].

Lutz, JE ;

Clemons, KV ;

Aristizabal, BH ;

Stevens, DA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (07) :1558-1561

[16] In vitro activity of a new triazole antifungal agent, Sch 56592, against clinical isolates of filamentous fungi [J].

Marco, F ;

Pfaller, MA ;

Messer, SA ;

Jones, RN .

MYCOPATHOLOGIA, 1998, 141 (02) :73-77

[17] Treatment of Scedosporium apiospermum brain abscesses with posaconazole [J].

Mellinghoff, IK ;

Winston, DJ ;

Mukwaya, G ;

Schiller, GJ .

CLINICAL INFECTIOUS DISEASES, 2002, 34 (12) :1648-1650

[18]

National Committee for Clinical Laboratory Standards, 2002, M27A2 NCCLS

[19] Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States [J].

Ostrosky-Zeichner, L ;

Rex, JH ;

Pappas, PG ;

Hamill, RJ ;

Larsen, RA ;

Horowitz, HW ;

Powderly, WG ;

Hyslop, N ;

Kauffman, CA ;

Cleary, J ;

Mangino, JE ;

Lee, J .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (10) :3149-3154

[20] Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp and Saccharomyces cerevisiae [J].

Pfaller, MA ;

Messer, S ;

Jones, RN .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (02) :233-235